Answers are grounded in this paper and cite their sources.
Sarcopenic obesity is a simultaneous combination of sarcopenia and obesity combined in pathological synergy by biochemical, pathophysiological and clinical mechanisms. Sarcopenia is associated with a decrease in nutritional status, low intake of protein and essential amino acids in the diet. Despite the presence of excess adipose tissue, especially visceral localization, with obesity and sarcopenic obesity, the patient’s body may experience a deficiency of proteins and amino acids. The long-term chronic inflammation associated with obesity and the excess of cytokines circulating in the blood create conditions for skeletal muscle catabolism. When splitting fats and carbohydrates, it is impossible to make up for the nitrogen deficiency found in proteins. Therefore, for the treatment of sarcopenic obesity, a sufficiently large intake of proteins from the diet is necessary. Dietary supplements of proteins and essential amino acids, including branched-chain amino acids (BCAAs, branched-chain amino acids), can be used to preserve and prevent catabolism of muscle tissue. BCAAs include leucine, isoleucine, and valine, which in various proportions, usually with a predominance of leucine, are included in nutritional support medications. BCAAs are widely used in amateur and professional sports. The possibility of using BCAA supplements for patients with sarcopenic obesity as part of a comprehensive treatment is of interest.
No takes yet. Share an insight, caveat, or question.
Kurmaev et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: